Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. ACC Action Center

Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive

Akshay Desai at ACC
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    ACC.24 - Akshay Desai shares the findings of the phase 2 KARDIA-2 trial. “Treatment with zilebesiran seems to be an effective therapy to incrementally reduce blood pressure in patients with mild-to-moderate hypertension despite treatment with indapamide, amlodipine or olmesartan”, says Akshay Desai.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Akshay Suvas Desai, MD is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital, Boston, MA, US. In addition, he is an associate professor of medicine at Harvard Medical School, Boston, MA, US.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of KARDIA-2

    Release date: 17 april 2024

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - Akshay Desai shares the findings of the phase 2 KARDIA-2 trial. “Treatment with zilebesiran seems to be an effective therapy to incrementally reduce blood pressure in patients with mild-to-moderate hypertension despite treatment with indapamide, amlodipine or olmesartan”, says Akshay Desai.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Akshay Suvas Desai, MD is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital, Boston, MA, US. In addition, he is an associate professor of medicine at Harvard Medical School, Boston, MA, US.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of KARDIA-2

    Release date: 17 april 2024

Schedule6 Oct 2024